Direkt zum Inhalt
Merck
Alle Fotos(1)

Wichtige Dokumente

Gesamtdokumentation anzeigen

R8404

Sigma-Aldrich

Rufinamid

≥98% (HPLC), powder

Synonym(e):

1-[(2,6-Difluorphenyl)-methyl]-1H-1,2,3-triazol-4 carboxamid

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C10H8F2N4O
CAS-Nummer:
106308-44-5
Molekulargewicht:
238.19
MDL-Nummer:
MFCD00865314
UNSPSC-Code:
12352200
PubChem Substanz-ID:
24724595
NACRES:
NA.77

Qualitätsniveau

100

Assay

≥98% (HPLC)

Form

powder

Farbe

white

Löslichkeit

DMSO: 9 mg/mL

Ersteller

Novartis

Lagertemp.

−20°C

SMILES String

NC(=O)c1cn(Cc2c(F)cccc2F)nn1

InChI

1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17)

InChIKey

POGQSBRIGCQNEG-UHFFFAOYSA-N

Angaben zum Gen

human ... SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Anwendung

Rufinamide has been used to test its analgesic effect on neuropathic pain in spared nerve injury (SNI) model.

Biochem./physiol. Wirkung

Rufinamide may elicit inhibition of the sodium channels and block action potential generation. This property makes it an antiepileptic drug for treating epilepsy disorders like Lennox-Gastaut syndrome.
Broad-spectrum anticonvulsant.

Leistungsmerkmale und Vorteile

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Diagnostische Implikationen

Effective therapy for partial seizures in adults and childhood seizures in Lennox-Gastaut syndrome.

Piktogramme

Health hazardExclamation mark
GHS08,GHS07

Signalwort

Warning

Gefahreneinstufungen

Carc. 2 - Repr. 2 - STOT SE 3

Zielorgane

Central nervous system

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number
106M4613V
124M4601V
021M4615V
056K46204
056K46203

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Suche nach COA

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 8

1 of 8

Lacosamid -Lösung 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

L-029

Lacosamid -Lösung

vibrant-m

Y0001982

Lacosamid

Levetiracetam ≥98% (HPLC)

Sigma-Aldrich

L8668

Levetiracetam

Teriflunomid ≥98% (HPLC)

Sigma-Aldrich

SML0936

Teriflunomid

Retigabin analytical standard

Supelco

90221

Retigabin

Retigabin ≥98% (HPLC)

Sigma-Aldrich

SML0325

Retigabin

Gabapentin solid

Sigma-Aldrich

G154

Gabapentin

Streptavidin Sepharose™ Hochleistung Cytiva 17-5113-01, pack of 5 mL

GE17-5113-01

Streptavidin Sepharose™ Hochleistung

K K Jain
Expert opinion on investigational drugs, 9(4), 829-840 (2000-11-04)
This article evaluates rufinamide, a new anti-epileptic drug (AED) in Phase III development. This review is done against the background of therapeutic challenges of epilepsy, old established AEDs, newly introduced AEDs and AEDs in clinical development. Pharmacological properties of 12
Emma D Deeks et al.
CNS drugs, 20(9), 751-760 (2006-09-07)
Rufinamide, a triazole derivative, reduces the recovery capacity of neuronal sodium channels after inactivation, limiting neuronal sodium-dependent action potential firing and mediating anticonvulsant effects. In children, adolescents and adults, adjunctive oral rufinamide was more effective than placebo in treating seizures
Paul L McCormack
PharmacoEconomics, 30(3), 247-256 (2012-02-16)
Rufinamide (Inovelon®), a triazole derivative, is an oral antiepileptic drug approved in the EU as adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients aged ≥4 years. The efficacy of oral rufinamide as adjunctive therapy
Marc R Suter et al.
Anesthesiology, 118(1), 160-172 (2012-12-12)
Voltage-gated sodium channels dysregulation is important for hyperexcitability leading to pain persistence. Sodium channel blockers currently used to treat neuropathic pain are poorly tolerated. Getting new molecules to clinical use is laborious. We here propose a drug already marketed as
Rainer Schimpf et al.
Heart rhythm, 9(5), 776-781 (2012-01-17)
The arrhythmogenic potential of short QT intervals has recently been highlighted in patients with a short QT syndrome. Drug-induced QT-interval prolongation is a known risk factor for ventricular tachyarrhythmias. However, reports on drug-induced QT-interval shortening are rare and proarrhythmic effects
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.